Prescription drug · ANDA
Doxycycline NDC 62135-725
Doxycycline 50 mg/1 · Tablet · Oral · Chartwell RX, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 62135-725-20 | 62135072520 | 20 TABLET in 1 BOTTLE (62135-725-20)Marketed from Jul 27, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Doxycycline
- Generic name (nonproprietary)
- doxycycline
- Active ingredients
- Doxycycline — 50 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Chartwell RX, LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 091605
- Marketing start
- Listing expires
- Other FDA classes
- Tetracyclines (Chemical structure)
- Identifiers
- Product ID 62135-725_45899031-dfb9-a7d6-e063-6294a90a80c6SPL ID 45899031-dfb9-a7d6-e063-6294a90a80c6SPL set ID 5bebf320-1395-43b9-9404-fe479d70b240RxCUI 1650142, 1652673UNII N12000U13OUPC 0362135725204, 0362135726201
- Pharmacologic class
- Tetracycline-class Drug
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N462135072520followed by a unit qualifier and the quantityPackage 62135-0725-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 091605
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Doxycycline | Doxycycline 100 mg/1 | TabletOral | Chartwell RX, LLC | 62135-726 |
| Doxycycline | Doxycycline 100 mg/1 | TabletOral | Proficient Rx LP | 82804-264 |
| Doxycycline | Doxycycline 100 mg/1 | TabletOral | Northwind Health Company, LLC | 51655-350 |
| Doxycycline | Doxycycline 100 mg/1 | TabletOral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-135 |
| Doxycycline | Doxycycline 50 mg/1 | TabletOral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-133 |
| Doxycycline | Doxycycline 75 mg/1 | TabletOral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-134 |
| Doxycycline | Doxycycline 150 mg/1 | TabletOral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-136 |
| Doxycycline | Doxycycline 100 mg/1 | TabletOral | A-S Medication Solutions | 50090-1462 |